RedHill Biopharma's partner, the University of Oklahoma, received a $2.9 million NCI grant to study opaganib's effectiveness with CAR T-cell therapy in cancer patients. This funding enables two phases of clinical trials, potentially validating opaganib's role in enhancing cancer treatment and offering a new revenue stream for RedHill.
The University of Oklahoma, a partner of RedHill Biopharma, secured a significant $2.9 million grant from the National Cancer Institute. This funding is specifically allocated to conduct Phase 1b and Phase 2 clinical trials investigating RedHill's drug, opaganib, in conjunction with CAR T-cell therapy for cancer treatment. This development is a positive catalyst for RedHill as it provides external funding for clinical development of one of its key assets, reducing R&D costs and potentially validating opaganib's efficacy in a high-impact therapeutic area. For traders, this represents a long-term opportunity if the trials are successful, but short-term impact might be moderate as clinical trials are lengthy and outcomes uncertain. The key opportunity lies in the potential for opaganib to become a standard adjunct to CAR T-cell therapy, significantly expanding its market.